Communiqués Leap Therapeutics, Inc.

Actions

LPTX

US52187K2006

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
2,43 ^USD	+2,97 %		+2,10 %	-41,38 %

14/05	LEAP THERAPEUTICS, INC. : HC Wainwright reste à l'achat	ZM
13/05	Leap Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Leap Therapeutics Announces $40 Million Private Placement	11/04	PR
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference	03/01	PR
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients	02/01	PR
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium	12/12	AQ
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference	21/11	PR
Leap Therapeutics Reports Third Quarter 2023 Financial Results	13/11	PR
Leap Therapeutics to Participate at Upcoming Investor Conferences	05/09/23	PR
Leap Therapeutics Reports Second Quarter 2023 Financial Results	15/08/23	AQ
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients	12/07/23	PR
Leap Therapeutics Announces Reverse Stock Split	20/06/23	PR
Leap Therapeutics Reports First Quarter 2023 Financial Results	16/05/23	AQ
Leap Therapeutics : Reports First Quarter 2023 Financial Results - Form 8-K	15/05/23	PU
LEAP THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	26/04/23	AQ
Leap Therapeutics : Announces Completion of Enrollment in Part A of the DeFianCe Study of - Form 8-K	12/04/23	PU
LEAP THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	12/04/23	AQ
Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients	12/04/23	PR
LEAP THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	07/04/23	AQ
Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results	27/03/23	AQ
LEAP THERAPEUTICS, INC. Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits (form 8-K/A)	24/03/23	AQ
LEAP THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	24/03/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Leap Therapeutics, Inc.

Actions

LPTX

US52187K2006

Communiqués

Filtres